





Case study





A 47 y/o woman developed synchronous ovarian and uterine endometrioid carcinomas (all stage I). The patient remained cancer-free until 7 years later when she present tumor recurrence showing poorly differentiated histology in the abdominal wall.





7 YRS




Immunostaining using antibodies against a panel of MMR gene products shows complete loss of PMS2 and MLH1 immunoreactivity in tumor cells, confirming MMR deficiency in both primary and recurrent tumors.



There are abundant tumor-infiltrating lymphocytes (CD8+ T cells illustrated). Many of the T cells also express PD-1 on cell surface, suggesting that PD-1 and PDL-1 pathway may operate within the tumor to inactivate immune response.



CD8+ cytotoxic T cells



PD-1+ T cells

